Michael H. Davidson - 02 Mar 2026 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role: Chief Executive Officer, Director
Signature: /s/ Michael H. Davidson
Issuer symbol: NAMS
Transactions as of: 02 Mar 2026
Net transactions value: -$14,753,258
Form type: 4
Filing time: 02 Mar 2026, 18:08:05 UTC
Previous filing: 26 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Davidson Michael H.	Chief Executive Officer, Director	C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS	/s/ Michael H. Davidson	02 Mar 2026	0001573785

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NAMS	Ordinary Shares	Options Exercise		+443,707	+255%		617,851	02 Mar 2026	Direct	F1
transaction	NAMS	Ordinary Shares	Sale	$14,753,258	-443,707	-72%	$33.25	174,144	02 Mar 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NAMS	Option (right to buy)	Options Exercise	$0	-443,707	-65%	$0.000000	239,267	02 Mar 2026	Ordinary Shares	443,707		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The exercise price of the option is EUR 1.16392.
F2	The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

Content

The exercise price of the option is EUR 1.16392.

The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.